1.
J Coll Physicians Surg Pak
; 18(3): 176-8, 2008 Mar.
Article
in English
| MEDLINE
| ID: mdl-18460249
ABSTRACT
Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response.